XML 31 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended
Jan. 31, 2012
Jan. 31, 2011
Cash flows from operating activities:    
Net loss $ (6,014) $ (11,007)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 540 780
Loss from equity investment 362 198
Accretion of redeemable preferred stock of subsidiary   525
Depreciation 1,449 1,634
Amortization of bond premium and interest expense on Series 1 Preferred 581 20
Other non-cash transactions (175) 11
Decrease (increase) in operating assets:    
Accounts receivable (1,942) (5,248)
Inventories (6,203) 1,052
Other assets (880) (1,610)
Increase (decrease) in operating liabilities:    
Accounts payable 3,919 (370)
Accrued liabilities (3,255) (249)
Deferred revenue (6,184) 12,111
Net cash used in operating activities (17,802) (2,153)
Cash flows from investing activities:    
Capital expenditures (926) (251)
Treasury notes matured 7,500 12,000
Treasury notes purchased   (21,996)
Net cash provided by (used in) investing activities 6,574 (10,247)
Cash flows from financing activities:    
Repayment of debt (55) (64)
Proceeds from debt   1,000
Payment of preferred dividends and return of capital (4,288) (800)
Proceeds from sale of common stock, net of registration fees 1,188 17,880
Net cash (used in) provided by financing activities (3,155) 18,016
Effects on cash from changes in foreign currency rates (2) 2
Net (decrease) increase in cash and cash equivalents (14,385) 5,618
Cash and cash equivalents-beginning of period 51,415 20,467
Cash and cash equivalents-end of period 37,030 26,085
Supplemental cash flow disclosures:    
Cash interest paid 63 54
Noncash financing and investing activity:    
Common stock issued in settlement of prior year bonus obligation 550 707
Common stock issued for Employee Stock Purchase Plan in settlement of prior year accrued employee contributions 84 58
Accrued sale of common stock, cash received in subsequent period   193
Accrued fees related to sale of common stock   $ 112